Press Releases

 
Press Releases
  Date Title and Summary View
Dec 8, 2017
INDIANAPOLIS, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the microbiome, today announced grants of options to fo...
Nov 8, 2017
INDIANAPOLIS, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the microbiome, today announced that Derek Small, chief...
Nov 2, 2017
INDIANAPOLIS, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB) ("Assembly" or the "Company"), a clinical-stage biotechnology company advancing a new class of oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutic candidates, which are designed to treat disord...
Nov 1, 2017
INDIANAPOLIS, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB) ("Assembly" or the "Company"), a clinical-stage biotechnology company advancing a new class of oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutic candidates, which are designed to treat disord...
Oct 5, 2017
INDIANAPOLIS, Oct. 05, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the microbiome, today announced grants of options to si...
Oct 2, 2017
INDIANAPOLIS, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the microbiome, today announced that it will have three...
Sep 25, 2017
INDIANAPOLIS, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the microbiome, today announced that it has selected a...
Aug 31, 2017
INDIANAPOLIS, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the microbiome, today announced participation at variou...
Jul 28, 2017
INDIANAPOLIS, July 28, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the microbiome, today announced grants of options to fi...
May 26, 2017
INDIANAPOLIS, May 26, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the microbiome, today announced presentations at two upc...
Page:
1
... NextLast
= add release to Briefcase



The Website contains information, news and/or press releases about the Company.  While this information was believed to be accurate as of the date it was prepared, the Company disclaims any duty or obligation to update this information, news or any press releases.

Investor Contact

investors@assemblybio.com